US FDA Staff Says Genentech, Inc.'s Avastin Brain Cancer Data Unclear

March 30, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, March 27 (Reuters) - It is difficult to tell how well brain cancer patients responded to Genentech Inc's cancer drug Avastin in early studies from the company, U.S. Food and Drug Administration staff said in documents released on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)